The U.S. government terminates a deal with Eli Lilly and Company for 350,856 remaining doses of the single antibody bamlanivimab that were scheduled to be delivered by the end of March. The deal will instead be focused on a supply of combined antibodies with etesevimab.
The U.S. government terminates a deal with Eli Lilly & Co. for 350,856 remaining doses of single antibody bamlanivimab that were scheduled to be delivered by the end of March 2021. It instead be focused on supply of combined antibodies with etesevimab.
The U.S. government terminates a deal with Eli Lilly & Co. for 350,856 remaining doses of thesingle antibody bamlanivimab that were scheduled to be delivered by the end of March. Thedealwillinstead be focused ona supply of combined antibodies with etesevimab.
The U.S. government terminates a deal with Eli Lilly and Company for 350,856 remaining doses of the single antibody bamlanivimab that were scheduled to be delivered by the end of March. The deal will instead be focused on a supply of combined antibodies with etesevimab.